BioAge Labs
Clinical-stage company targeting the biology of aging. Listed on Nasdaq in October 2024.
Impact Human Health™
Accelerating investor understanding of breakthrough science.
Thermal’s investor relations practice for pre-IPO & growth-stage, and public companies.
The opportunity
When the biggest stories in biotech break, Thermal is behind them.
From CRISPR and longevity to oncology and AI in medicine. That work now extends into investor relations — you won’t spend the first month teaching us your field.
AI in medicine
CRISPR
Longevity
Oncology
Drug discovery
Diagnostics
Cardiovascular
Track record
We’ve helped define categories, launch companies, and shape narratives that move markets.
Our advantage is simple: we already speak the language of the science.
Why IR sits with communications
The companies that get IR right don’t silo it from communications.
This practice exists because our clients asked for it.
Beyond the milestone
More than communications support around a financial event. We run the program.
Inside the process
Direct work with the exchange, the IR website, and the financial documents themselves.
One story, two audiences
How you tell your story to investors, not just the press — and the two reinforcing each other.
Who we work with
Two kinds of company.
Companies preparing to go public, or working toward a significant fundraise or financial milestone.
We manage the full program from early preparation through listing day and beyond.
What we manage
Exchange relationship
Investor narrative
IR website
Investor materials
Financial media strategy
Listing-day coordination
Listed companies that want an embedded IR partner working alongside the internal team.
We keep the investor story sharp and consistent through earnings cycles, market-moving transactions, and the moments that require getting the narrative exactly right.
Where we help
Earnings cycles, end to end
Financings & M&A
IR materials review & advisory
Some of our public company clients have been with us since before they listed.
THE PATH TO LISTING DAY
PHASE 01
Preparation
Initial conversations with Nasdaq or NYSE, requirements, and timeline. The investor narrative takes shape.
PHASE 02
Filing & materials
S-1 strategy with legal and banking. Roadshow deck, Q&A, and the IR website staged to disclosure standards.
PHASE 03
Listing day
The investor story and the public story land together, with media moments timed to the event.
PHASE 04
Beyond the bell
Earnings cadence, financings and M&A, and an embedded IR partner who already knows the story.
LIFE AS A PUBLIC COMPANY
An embedded partner.
Through every earnings cycle and corporate milestone.
We review and sharpen IR press releases, earnings scripts, prepared remarks, roadshow and investor day presentations, FAQs, and filings including 10-Ks — in coordination with your legal and finance teams.
The full cycle: pre-earnings preparation and message review, anticipated investor and analyst Q&A, and post-earnings follow-through.
We prepare your executives for the financial press, putting the relationships we’ve built to work when the timing counts, and positioning them for the moments that define how the Street sees them.
We guide companies through equity raises and acquisitions from announcement through market reaction, shaping the narrative investors hear and the materials that carry it.
How we work together
In close partnership with your teams.
Who we sit alongside
- Legal
- Registration statements, disclosure standards, and filing review.
- Banking
- Roadshow materials and the timeline around the raise or listing.
- Leadership
- The investor thesis, key messages, and preparation for the room.
- Internal IR & comms
- Embedded support, not a parallel track.
Where we plug in
Exchanges
Nasdaq · NYSE
IR platforms
Notified · Q4 · staging environments
Documents
S-1 · 10-K · earnings scripts · roadshow decks
One team across communications and IR. Nothing gets lost between them.
Recent engagements
Proof, not a pitch.
The same team before and after listing day.
Scribe Therapeutics
Clinical-stage CRISPR company first targeting CVD, co-founded by Jennifer Doudna. Listed on the Nasdaq in July 2026.
Investment
One retainer. No project fees.
The IPO process is included, not a separate project fee. The retainer steps up for active preparation, then settles back down once you’re public.
The step-up is agreed at signing, against a named trigger — underwriter selection, S-1 filing, or roadshow prep. No renegotiation mid-process.
Ask us what it costs →